文献速递银屑病与炎症性皮肤病

新发银屑病中的司库奇尤单抗治疗:旨在理解疾病修饰潜力的随机多中心STEPIn研究的基本原理与设计

Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-07-15

STEPIn研究(NCT03020199)是一项随机多中心研究,旨在探讨新发(≤12个月)中重度斑块状银屑病患者早期干预(司库奇尤单抗300 mg vs 窄谱紫外线B光疗)能否改变疾病自然病程。研究纳入160例18-50岁未接受过系统治疗和光疗的患者,主要研究含两个治疗组,治疗停止后随访至第208周,并设机制亚研究评估免疫学变化。

要点

  • STEPIn研究比较司库奇尤单抗300 mg与窄谱紫外线B光疗在新发银屑病中的早期干预效果。
  • 纳入160例18-50岁、病程≤12个月、未接受过系统治疗和光疗的中重度斑块状银屑病患者。
  • 主要研究含两个治疗组,治疗停止后随访至第208周以监测疾病活动。

核心结论

  • STEPIn是首个研究新发银屑病早期强化治疗能否改变疾病长期自然病程并成为银屑病患者新治疗策略的研究。

研究设计与样本

  • 随机、多中心研究,纳入160例18-50岁、新发(≤12个月)中重度斑块状银屑病且未接受过系统治疗和光疗的患者。
  • 主要研究含两个治疗组:A1组为皮下注射司库奇尤单抗300 mg,基线、第1、2、3、4周给药,此后每4周一次直至并包括第52周;B1组为1或2个周期窄谱紫外线B光疗,每周期12周,周期之间最长休息28周。
  • 治疗停止后随访监测疾病活动至第208周。
  • 机制亚研究将评估皮肤活检中的免疫学变化和致病性组织驻留记忆T细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, biological treatments have been assessed in subjects with a long-term history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid arthritis and other immune-mediated inflammatory diseases, early intensive systemic treatment prolongs treatment-free remission. We hypothesize that, by treating patients with psoriasis early with an effective systemic therapy, we may be able to alter the clinical outcome and the natural course of the disease. The STEPIn study (NCT03020199) investigates early intervention with secukinumab versus narrow-band ultraviolet B (nb-UVB) phototherapy in subjects with new-onset psoriasis. OBJECTIVE: To determine whether early intervention with either nb-UVB treatment or secukinumab in subjects with new-onset plaque psoriasis might modify the natural course of the disease. METHODS: One hundred and sixty subjects aged 18-50 years with new-onset (≤12 months) moderate-to-severe plaque psoriasis and naïve to systemic treatment and phototherapy will be randomized to secukinumab 300 mg or nb-UVB. The Main Study has two treatment arms: Arm A1, subcutaneous secukinumab 300 mg at baseline, Weeks 1, 2, 3 and 4, and every 4 weeks thereafter until and including Week 52; Arm B1, one/two cycles of nb-UVB for 12 weeks each (maximum 28-week break between cycles). After treatment discontinuation, patients will be followed up and monitored for disease activity up to Week 208. A Mechanistic Sub-study will assess immunological changes and pathogenic tissue-resident memory T cells in skin biopsies. CONCLUSIONS: STEPIn is the first study to investigate whether early intensive treatment in new-onset psoriasis can modify the long-term natural course of the disease and thus become a novel treatment strategy for patients with psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018. PMID: 29633373. doi:10.1111/jdv.14979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。